Developments Vertex Pharma’s KALYDECO gets FDA approval for use in infants with CF Vertex Pharma’s (NASDAQ:VRTX) KALYDECO obtained FDA approval for use in infants with cystic fibrosis (CF) between the ages of six and 12 months. KALYDECO is indicated in CF patients who have at least one mutation in the... April 30, 2019